EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 0.1812
March 31, 2026 -0.459
December 31, 2025 0.9231
September 30, 2025 -0.0797
June 30, 2025 -0.4016
March 31, 2025 -0.374
December 31, 2024 -0.3741
September 30, 2024 -0.4411
June 30, 2024 -0.5145
March 31, 2024 -0.5116
December 31, 2023 -0.4619
September 30, 2023 -0.5075
June 30, 2023 -0.9102
March 31, 2023 -3.237
December 31, 2022 -1.069
September 30, 2022 -1.333
June 30, 2022 -1.503
March 31, 2022 -0.9162
December 31, 2021 -1.222
Date Value
September 30, 2021 -1.424
June 30, 2021 -1.247
March 31, 2021 -1.196
December 31, 2020 -0.8785
September 30, 2020 -0.9246
June 30, 2020 -1.242
March 31, 2020 -5.471
December 31, 2019 -3.305
September 30, 2019 -3.317
June 30, 2019 -3.652
March 31, 2019 -4.659
December 31, 2018 -3.468
September 30, 2018 -4.511
June 30, 2018 -5.00
March 31, 2018 -8.50
December 31, 2017 -6.50
September 30, 2017 -7.30
June 30, 2017 -7.40
March 31, 2017 -13.90

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
Indaptus Therapeutics, Inc. -0.0155
ACADIA Pharmaceuticals, Inc. 0.1822
Alnylam Pharmaceuticals, Inc. 1.207
Savara, Inc. -0.1587
Vericel Corp. 0.0422

EPS Diluted (Quarterly) Related Metrics